The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A twice-daily or a three-times-daily tegafur-uracil and leucovorin calcium regimen as adjuvant therapy in patients with resected colorectal cancer: A phase III study.
 
Kazuya Iwamoto
No Relationships to Disclose
 
Taishi Hata
No Relationships to Disclose
 
Masakazu Miyake
No Relationships to Disclose
 
Masayuki Ohue
Honoraria - Chugai Pharma
Research Funding - Taiho Pharmaceutical
 
Tatsushi Shingai
No Relationships to Disclose
 
Mitsuyoshi Tei
No Relationships to Disclose
 
Hiroyoshi Takemoto
No Relationships to Disclose
 
Masakazu Ikenaga
No Relationships to Disclose
 
Yujiro Fujie
No Relationships to Disclose
 
Norikatsu Miyoshi
No Relationships to Disclose
 
Hidekazu Takahashi
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Chu Matsuda
No Relationships to Disclose
 
Tsunekazu Mizushima
Consulting or Advisory Role - Takeda
Speakers' Bureau - Abbvie; EA Pharma; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical; Takeda
 
Kohei Murata
No Relationships to Disclose
 
Yuko Ohno
No Relationships to Disclose
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Hidetoshi Eguchi
No Relationships to Disclose